Emergent BioSolutions Balance Sheet Health
Financial Health criteria checks 3/6
Emergent BioSolutions has a total shareholder equity of $508.4M and total debt of $662.6M, which brings its debt-to-equity ratio to 130.3%. Its total assets and total liabilities are $1.5B and $969.4M respectively.
Key information
130.3%
Debt to equity ratio
US$662.60m
Debt
| Interest coverage ratio | n/a |
| Cash | US$149.90m |
| Equity | US$508.40m |
| Total liabilities | US$969.40m |
| Total assets | US$1.48b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ER4's short term assets ($661.4M) exceed its short term liabilities ($229.9M).
Long Term Liabilities: ER4's short term assets ($661.4M) do not cover its long term liabilities ($739.5M).
Debt to Equity History and Analysis
Debt Level: ER4's net debt to equity ratio (100.8%) is considered high.
Reducing Debt: ER4's debt to equity ratio has increased from 80% to 130.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ER4 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ER4 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 31.1% per year.